GT Biopharma, Inc.
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-144.2M | $9.8M | $-21.5M | $-23.5M | $-501.0K | $-5.2M | $-3.7M | $-3.0M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $2.0K | $1.0K | $2.0K | $0 | — | — | — | — |
| Amortization | $0 | $0 | $0 | $22.0K | $2.0K | $3.0K | $23.0K | $31.0K |
| Stock-Based Compensation | $130.1M | $6.6M | $3.8M | $2.6M | $176.0K | $929.0K | $307.0K | $149.0K |
| Net Cash from Operating Activities | $-5.4M | $-1.9M | $-4.7M | $-1.7M | $-442.0K | $-987.0K | $-963.0K | $-1.5M |
| Investing Activities | ||||||||
| Capital Expenditures | $4.0K | $0 | $1.0K | $6.0K | $0 | $2.0K | $0 | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-4.0K | $0 | $-1.0K | $-6.0K | $0 | $-2.0K | $0 | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $6.0M | $1.9M | $3.9M | $2.6M | $425.0K | $930.0K | $1.0M | $296.0K |
| Net Change in Cash | $557.0K | $-28.0K | $-808.0K | $812.0K | $-80.0K | $31.0K | $38.0K | $-1.2M |
| Free Cash Flow | $-5.4M | $-1.9M | $-4.7M | $-1.8M | $-442.0K | $-989.0K | $-963.0K | — |